Each unit in the offering consists of a share of common stock, 0.75 of a Series A warrant to purchase common stock at 87¢, a Series B warrant to purchase common stock and 0.75 of a Series A warrant to purchase common stock at 75¢, according to Delcath.
Roth Capital Partners will be the sole manager for the offering, Delcath said.
Net proceeds are expected to be approximately $6.2 million for the New York, N.Y.-based company. The offering is slated to close July 21.
Earlier this month, Delcath agreed to pay $8.5 million to settle a clutch of lawsuits filed by shareholders over losses related to its development of the drug-device combination Melblez kit. The lawsuits sought compensation for losses stemming from 3 separate incidents the plaintiffs claim caused share prices to drop significantly.